A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularcancerheartiicoronary
  Phrases that lowered it: dosemgpharmacokineticsevaluatevisit
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 4.0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 27.4% (raises risk) · Drug's FDA history
• Sponsor's past trials: 506 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 7 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 5 (lowers risk) · Design
• Drug's FAERS reports marked serious: 97.9% (raises risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 10 (lowers risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma NCT01969565 · started 2013 · scored riskier than 95% of active trials terminated
• Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients NCT02177682 · started 2014 · scored riskier than 20% of active trials terminated
• A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma NCT03697629 · started 2018 · scored riskier than 82% of active trials completed
• A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide NCT03215524 · started 2017 · scored riskier than 73% of active trials completed
• Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma NCT02332850 · started 2015 · scored riskier than 74% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.